{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T08:39:06Z","timestamp":1781944746079,"version":"3.54.5"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Background: The lead mobilization test reflects the mobilizable and likely toxicologically active fraction of the lead body burden. We propose a safe and convenient protocol for this test, to assess concomitant copper and zinc excretion and to determine the size of the chelatable lead pool in nonoccupationally exposed adults.<\/jats:p><jats:p>Methods: The study population included 80 white adults: 40 controls [median blood lead concentration (PbB), 25 \u03bcg\/L] and 40 lead-exposed individuals (315 \u03bcg\/L). After collection of 4- and 24-h baseline urine specimens and a blood sample, dimercaptosuccinic acid (DMSA) was administered orally (1 g), and additional 4- and 24-h urine specimens were obtained. Determinants of the chelatable urinary lead (DMSA-PbU) were traced by linear regression analysis.<\/jats:p><jats:p>Results: Urinary DMSA and lead excretion peaked within 2\u20133 h after DMSA administration. The amounts of DMSA, lead, copper, and zinc recovered in the 4-h urinary collections were highly correlated with those in 24-h collections (r = 0.857, 0.859, 0.958, and 0.757, respectively). At PbB concentrations &amp;gt;300 \u03bcg\/L, the relationship between DMSA-PbU and PbB showed a steep increase and a widespread dispersion of DMSA-PbU around the regression line. After DMSA, copper and zinc excretion rates were increased up to 91- and 33-fold, respectively. No side effects were reported after DMSA.<\/jats:p><jats:p>Conclusions: Determination of DMSA-PbU in a 4-h collection after DMSA is convenient, apparently safe, and inexpensive. An upper reference limit value of 22 \u03bcg\/4 h is proposed for Belgian reference individuals. The diagnostic value of DMSA-PbU is likely to be contributive for PbB &amp;gt;300 \u03bcg\/L.<\/jats:p>","DOI":"10.1373\/clinchem.2005.051128","type":"journal-article","created":{"date-parts":[[2005,10,26]],"date-time":"2005-10-26T07:33:09Z","timestamp":1130311989000},"page":"88-96","source":"Crossref","is-referenced-by-count":21,"title":["Clinical Evaluation of a Lead Mobilization Test Using the Chelating Agent Dimercaptosuccinic Acid"],"prefix":"10.1093","volume":"52","author":[{"given":"Perrine","family":"Hoet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Buchet","sequence":"first","affiliation":[{"name":"Unit of Industrial Toxicology and Occupational Medicine, Faculty of Medicine, Catholic University of Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Decerf","sequence":"first","affiliation":[{"name":"Unit of Industrial Toxicology and Occupational Medicine, Faculty of Medicine, Catholic University of Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoi\u0302t","family":"Lavalleye","sequence":"first","affiliation":[{"name":"Unit of Industrial Toxicology and Occupational Medicine, Faculty of Medicine, Catholic University of Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Haufroid","sequence":"first","affiliation":[{"name":"Unit of Industrial Toxicology and Occupational Medicine, Faculty of Medicine, Catholic University of Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Lison","sequence":"first","affiliation":[{"name":"Unit of Industrial Toxicology and Occupational Medicine, Faculty of Medicine, Catholic University of Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,1,1]]},"reference":[{"key":"2020022801102182500_R1","doi-asserted-by":"crossref","unstructured":"Romieu I, Lacasana M, McConnell R. Lead exposure in Latin America and the Caribbean. Lead Research Group of the Pan-American Health Organization. Environ Health Perspect1997;105:398-405.","DOI":"10.1289\/ehp.97105398"},{"key":"2020022801102182500_R2","unstructured":"Tong S, von Schirnding YE, Prapamontol T. Environmental lead exposure: a public health problem of global dimensions. Bull World Health Organ2000;78:1068-1077."},{"key":"2020022801102182500_R3","unstructured":"Krishnaswamy K, Kumar BD. Lead toxicity. Indian Pediatr1998;35:209-216."},{"key":"2020022801102182500_R4","doi-asserted-by":"crossref","unstructured":"Srianujata S. Lead\u2014the toxic metal to stay with human. J Toxicol Sci1998;23(Suppl 2):237-240.","DOI":"10.2131\/jts.23.SupplementII_237"},{"key":"2020022801102182500_R5","doi-asserted-by":"crossref","unstructured":"Hernberg S. Lead poisoning in a historical perspective. Am J Ind Med2000;38:244-254.","DOI":"10.1002\/1097-0274(200009)38:3<244::AID-AJIM3>3.0.CO;2-F"},{"key":"2020022801102182500_R6","unstructured":"International Agency for Research on Cancer. Inorganic and organic lead compounds. IARC monographs on the evaluation of carcinogenic risks to humans Vol. 87, 10\u201317 February 2004. http:\/\/www-cie.iarc.fr\/htdocs\/announcements\/vol87.htm (accessed March 2005).."},{"key":"2020022801102182500_R7","doi-asserted-by":"crossref","unstructured":"Lauwerys R, Hoet P. Industrial chemical exposure: guidelines for biological monitoring, 3rd ed2000:638pp Lewis Publishers Boca Raton, FL. .","DOI":"10.1201\/9781482293838"},{"key":"2020022801102182500_R8","unstructured":"Skerfving S, Nilsson U, Schutz A, Gerhardsson L. Biological monitoring of inorganic lead. Scand J Work Environ Health1993;19(Suppl 1):59-64."},{"key":"2020022801102182500_R9","doi-asserted-by":"crossref","unstructured":"Graziano JH. Validity of lead exposure markers in diagnosis and surveillance. Clin Chem1994;40:1387-1390.","DOI":"10.1093\/clinchem\/40.7.1387"},{"key":"2020022801102182500_R10","doi-asserted-by":"crossref","unstructured":"Sakai T. Biomarkers of lead exposure. Ind Health2000;38:127-142.","DOI":"10.2486\/indhealth.38.127"},{"key":"2020022801102182500_R11","doi-asserted-by":"crossref","unstructured":"Apostoli P, Porru S, Duca P, Ferioli A, Alessio L. Significance and validity of a shortened lead chelation test. J Occup Med1990;32:1124-1129.","DOI":"10.1097\/00043764-199011000-00016"},{"key":"2020022801102182500_R12","doi-asserted-by":"crossref","unstructured":"Lee BK, Schwartz BS, Stewart W, Ahn KD. Provocative chelation with DMSA and EDTA: evidence for differential access to lead storage sites. Occup Environ Med1995;52:13-19.","DOI":"10.1136\/oem.52.1.13"},{"key":"2020022801102182500_R13","doi-asserted-by":"crossref","unstructured":"Schwartz BS, Lee B-K, Stewart W, Sithisarankul P, Stickland PT, Ahn K-D, et al. \u03b4-Aminolevulinic acid dhehydratase genotype modifies four hour urinary lead excretion after oral administration of dimercaptosuccinic acid. Occup Environ Med1997;54:241-246.","DOI":"10.1136\/oem.54.4.241"},{"key":"2020022801102182500_R14","doi-asserted-by":"crossref","unstructured":"Markowitz ME, Rosen JF. Assessment of lead stores in children: validation of an 8-hour CaNa2EDTA provocative test. J Pediatr1984;104:337-341.","DOI":"10.1016\/S0022-3476(84)81091-4"},{"key":"2020022801102182500_R15","doi-asserted-by":"crossref","unstructured":"Lee B-K, Ahn K-D, Lee S-S, Lee G-S, Kim Y-B, Schwartz BS. A comparison of different lead biomarkers in their associations with lead-related symptoms. Int Arch Occup Environ Health2000;73:298-304.","DOI":"10.1007\/s004200000132"},{"key":"2020022801102182500_R16","doi-asserted-by":"crossref","unstructured":"Porru S, Alessio L. The use of chelating agents in occupational lead poisoning. Occup Med1996;46:41-48.","DOI":"10.1093\/occmed\/46.1.41"},{"key":"2020022801102182500_R17","doi-asserted-by":"crossref","unstructured":"Prerovska I, Teisinger J. Excretion of lead and its biological activity several years after termination of exposure. Br J Ind Med1970;27:352-355.","DOI":"10.1136\/oem.27.4.352"},{"key":"2020022801102182500_R18","doi-asserted-by":"crossref","unstructured":"Alessio L, Castoldi MR, Odone P, Franchini I. Behaviour of indicators of exposure and effect after cessation of occupational exposure to lead. Br J Ind Med1981;38:262-267.","DOI":"10.1136\/oem.38.3.262"},{"key":"2020022801102182500_R19","doi-asserted-by":"crossref","unstructured":"Schutz A, Skerfving S, Christoffersson JO, Ahlgren L, Mattson S. Lead in vertebral bone biopsies from active and retired lead workers. Arch Environ Health1987;42:340-346.","DOI":"10.1080\/00039896.1987.9934356"},{"key":"2020022801102182500_R20","doi-asserted-by":"crossref","unstructured":"Batuman V, Maesaka JK, Haddad B, Tepper E, Landy E, Wedeen RP. The role of lead in gout nephropathy. N Engl J Med1981;304:520-523.","DOI":"10.1056\/NEJM198102263040905"},{"key":"2020022801102182500_R21","doi-asserted-by":"crossref","unstructured":"Batuman V, Landy E, Maesaka JK, Wedeen RP. Contribution of lead to hypertension with renal impairment. N Engl J Med1983;309:17-21.","DOI":"10.1056\/NEJM198307073090104"},{"key":"2020022801102182500_R22","doi-asserted-by":"crossref","unstructured":"Colleoni N, D\u2019Amico G. Chronic lead accumulation as possible cause of renal failure in gouty patients. Nephron1986;44:32-35.","DOI":"10.1159\/000183908"},{"key":"2020022801102182500_R23","doi-asserted-by":"crossref","unstructured":"Craswell PW, Price J, Boyle PD, Heazlewood VJ, Baddeley H, Lloyd HM, et al. Chronic renal failure with gout: a marker of chronic lead poisoning. Kidney Int1984;26:319-323.","DOI":"10.1038\/ki.1984.175"},{"key":"2020022801102182500_R24","doi-asserted-by":"crossref","unstructured":"Bennett WM. Lead nephropathy. Kidney Int1985;28:212-220.","DOI":"10.1038\/ki.1985.143"},{"key":"2020022801102182500_R25","doi-asserted-by":"crossref","unstructured":"Sokas RK, Atleson J, Keogh JP. Shortened forms of provocative lead chelation. J Occup Med1988;30:420-424.","DOI":"10.1097\/00043764-198805000-00008"},{"key":"2020022801102182500_R26","unstructured":"Cullen G, Dines A, Kolev S. IPCSINTOX databank. Monograph for UKPID. Lead. http:\/\/www.intox.org\/databank\/documents\/chemical\/lead\/ukpid25.htm (accessed March 2005).."},{"key":"2020022801102182500_R27","unstructured":"Cory-Slechta D, Weiss B, Cox C. Mobilization and redistribution of lead over the course of CaEDTA chelation therapy. J Pharmacol Exp Ther1987;243:804-813."},{"key":"2020022801102182500_R28","unstructured":"Centers for Disease Control and Prevention. National Center for Environmental Health. Preventing lead poisoning in young children. A statement by the Centers for Disease Control and Prevention\u2013October 1991. http:\/\/www.cdc.gov\/nceh\/lead\/publications\/books\/plpyc\/contents.htm (accessed March 2005).."},{"key":"2020022801102182500_R29","doi-asserted-by":"crossref","unstructured":". American Academy of Pediatrics Committee on Drugs. Treatment guidelines for lead exposure in children. Pediatrics1995;96:155-160.","DOI":"10.1542\/peds.96.1.155"},{"key":"2020022801102182500_R30","unstructured":"Graziano G, Howland M. Antidotes in depth: succimer (2,3-dimercaptosuccinic acid). Goldfrank L Flomenbaum N Lewin N Weisman R Howland MAet al eds. Goldfrank\u2019s toxicologic emergencies 6th ed1998:1310-1314 Appleton & Lange Stamford. ."},{"key":"2020022801102182500_R31","doi-asserted-by":"crossref","unstructured":"Graziano JH, Siris E, Lolacono N, Silverberg SJ, Turgeon L. 2,3-Dimercaptosuccinic acid as an antidote for lead intoxication. Clin Pharmacol Ther1985;37:431-438.","DOI":"10.1038\/clpt.1985.67"},{"key":"2020022801102182500_R32","doi-asserted-by":"crossref","unstructured":"Aposhian HV, Aposhian MM. meso-2,3-Dimercaptosuccinic acid: chemical, pharmacological, and toxicological properties of an orally effective metal chelating agent. Annu Rev Pharmacol Toxicol1990;30:279-306.","DOI":"10.1146\/annurev.pa.30.040190.001431"},{"key":"2020022801102182500_R33","unstructured":"Cory-Slechta D. Mobilization of lead over the course of DMSA chelation therapy and long-term efficacy. J Pharmacol Exp Ther1988;246:84-91."},{"key":"2020022801102182500_R34","doi-asserted-by":"crossref","unstructured":"Bentur Y, Brook JG, Behar R, Taitelman U. meso-2,3-Dimercaptosuccinic acid in the diagnosis and treatment of lead poisoning. J Toxicol Clin Toxicol1987;25:39-51.","DOI":"10.3109\/15563658708992612"},{"key":"2020022801102182500_R35","doi-asserted-by":"crossref","unstructured":"Gerhardsson L, Borjesson J, Mattsson S, Schutz A, Skerfving S. Chelatable lead in relation to lead in bone and ALAD genotype. Environ Res1999;80:389-398.","DOI":"10.1006\/enrs.1998.3936"},{"key":"2020022801102182500_R36","doi-asserted-by":"crossref","unstructured":"Maiorino RM, Aposhian HV, Bruce D. Determination and metabolism of dithiol chelating agents. VI. Isolation and identification of the mixed disulfides of meso-2,3-dimercaptosuccinic acid with l-cysteine in human urine. Toxicol Appl Pharmacol1989;97:338-349.","DOI":"10.1016\/0041-008X(89)90338-4"},{"key":"2020022801102182500_R37","doi-asserted-by":"crossref","unstructured":"Asiedu P, Moulton T, Blum CB, Roldan E, Lolacono NJ, Graziano JH. Metabolism of meso-2,3-dimercaptosuccinic in lead-poisoned children and normal adults. Environ Health Perspect1995;103:734-739.","DOI":"10.1289\/ehp.95103734"},{"key":"2020022801102182500_R38","doi-asserted-by":"crossref","unstructured":"Dart C, Hurlbut MK, Maiorino RM, Mayersohn M, Aposhian HV, Hanssen LV. Pharmacokinetics of meso-2,3-dimercaptosuccinic acid in patients with lead poisoning and in healthy adults. J Pediatr1994;125:309-316.","DOI":"10.1016\/S0022-3476(94)70217-9"},{"key":"2020022801102182500_R39","doi-asserted-by":"crossref","unstructured":"Schwartz BS, Lee B-K, Lee G-S, Stewart WF, Lee S-S, Hwang K-Y, et al. Associations of blood lead, dimercaptosuccinic acid-chelatable lead, and tibia lead with neurobehavioral test scores in South Korean lead workers. Am J Epidemiol2001;153:453-464.","DOI":"10.1093\/aje\/153.5.453"},{"key":"2020022801102182500_R40","doi-asserted-by":"crossref","unstructured":"Todd AC, Lee B-K, Lee G-S, Ahn K-D, Moshier EL, Schwartz BS. Predictors of DMSA chelatable lead, tibial lead, and blood lead in 802 Korean lead workers. Occup Environ Med2001;58:73-80.","DOI":"10.1136\/oem.58.2.73"},{"key":"2020022801102182500_R41","unstructured":"Mann KV, Travers JD. Succimer, an oral chelator. Clin Pharm1991;10:914-922."},{"key":"2020022801102182500_R42","doi-asserted-by":"crossref","unstructured":"Chisholm JJ. Safety and efficacy of meso-2,3-dimercaptosuccinic acid (DMSA) in children with elevated blood lead concentrations. J Toxicol Clin Toxicol2000;38:365-375.","DOI":"10.1081\/CLT-100100945"},{"key":"2020022801102182500_R43","doi-asserted-by":"crossref","unstructured":"Ding G-Sh, Liang Y-Y. Antidotal effects of dimercaptosuccinic acid. J Appl Toxicol1991;11:7-14.","DOI":"10.1002\/jat.2550110103"},{"key":"2020022801102182500_R44","doi-asserted-by":"crossref","unstructured":"Fournier L, Thomas G, Garnier R, Buisine A, Houze P, Pradier F, et al. 2,3-Dimercaptosuccinic acid treatment of heavy metal poisoning in humans. Med Toxicol Adverse Drug Exp1988;3:499-504.","DOI":"10.1007\/BF03259898"},{"key":"2020022801102182500_R45","doi-asserted-by":"crossref","unstructured":"Freidheim E, Graziano JH, Popovac D, Dragovic D, Kaul B. Treatment of lead poisoning by 2,3-dimercaptosuccinic acid. Lancet1978;ii:1234-1236.","DOI":"10.1016\/S0140-6736(78)92103-7"},{"key":"2020022801102182500_R46","doi-asserted-by":"crossref","unstructured":"Graziano JH, Leong JK, Freidheim E. 2,3-Dimercaptosuccinic acid: a new agent for the treatment of lead poisoning. J Pharmacol Exp Ther1978;206:696-700.","DOI":"10.1203\/00006450-197804001-00259"},{"key":"2020022801102182500_R47","doi-asserted-by":"crossref","unstructured":"Domingo JL, Paternain JL, Llobet JM, Corbella J. Developmental toxicity of subcutaneously administered meso-2,3-dimercaptosuccinic acid in mice. Fundam Appl Toxicol1988;11:715-722.","DOI":"10.1016\/0272-0590(88)90134-0"},{"key":"2020022801102182500_R48","doi-asserted-by":"crossref","unstructured":"Domingo JL, Ortega A, Paternain JL, Llobet JM, Corbella J. Oral meso-2,3-dimercaptosuccinic acid in pregnant Sprague-Dawley rats: teratogenicity and alterations in mineral metabolism. I. Teratological evaluation. J Toxicol Environ Health1990;30:181-190.","DOI":"10.1080\/15287399009531421"},{"key":"2020022801102182500_R49","doi-asserted-by":"crossref","unstructured":"Paternain JL, Ortega A, Domingo JL, Llobet JM, Corbella J. Oral meso-2,3-dimercaptosuccinic acid in pregnant Sprague-Dawley rats: teratogenicity and alterations in mineral metabolism. II. Effect on mineral metabolism. J Toxicol Environ Health1990;30:191-197.","DOI":"10.1080\/15287399009531422"},{"key":"2020022801102182500_R50","doi-asserted-by":"crossref","unstructured":"Taubeneck MW, Domingo JL, Llobet JM, Keen CL. meso-2,3-Dimercaptosuccinic acid (DMSA) affects maternal and fetal copper metabolism in Swiss mice. Toxicology1992;72:27-40.","DOI":"10.1016\/0300-483X(92)90083-Q"},{"key":"2020022801102182500_R51","doi-asserted-by":"crossref","unstructured":"Schwartz BS, Stewart WF, Todd AC, Links JM. Predictors of dimercaptosuccinic acid chelatable lead and tibial lead in former organolead manufacturing workers. Occup Environ Med1999;56:22-29.","DOI":"10.1136\/oem.56.1.22"},{"key":"2020022801102182500_R52","unstructured":"Griffin TB, Coulston F, Wills H, Russell JC. Clinical studies on men continuously exposed to airborne particulate lead. Environ Qual Saf Suppl1975;2:221-240."},{"key":"2020022801102182500_R53","doi-asserted-by":"crossref","unstructured":"Brunekreef B. The relationship between air lead and blood lead in children: a critical review. Sci Total Environ1984;38:79-123.","DOI":"10.1016\/0048-9697(84)90210-9"},{"key":"2020022801102182500_R54","doi-asserted-by":"crossref","unstructured":"Manton WI, Cook JD. High accuracy (stable isotope dilution) measurements of lead in serum and cerebrospinal fluid. Br J Ind Med1984;41:313-319.","DOI":"10.1136\/oem.41.3.313"},{"key":"2020022801102182500_R55","doi-asserted-by":"crossref","unstructured":"Schutz A, Bergdahl IA, Ekholm A, Skerfving S. Measurement by ICP-MS of lead in plasma and whole blood of lead workers and controls. Occup Environ Med1996;53:736-740.","DOI":"10.1136\/oem.53.11.736"},{"key":"2020022801102182500_R56","doi-asserted-by":"crossref","unstructured":"Hernandez-Avila M, Smith D, Meneses F, Sanin LH, Hu H. The influence of bone and blood lead on plasma lead levels in environmentally exposed adults. Environ Health Perspect1998;106:473-477.","DOI":"10.1289\/ehp.106-1533211"},{"key":"2020022801102182500_R57","doi-asserted-by":"crossref","unstructured":"Bergdahl IA, Sheveleva M, Schutz A, Artamonova VG, Skerfving S. Plasma and blood lead in humans: capacity-limited binding to delta-aminolevulinic acid dehydratase and other lead-binding components. Toxicol Sci1998;46:247-253.","DOI":"10.1093\/toxsci\/46.2.247"},{"key":"2020022801102182500_R58","doi-asserted-by":"crossref","unstructured":"Smith D, Hernandez-Avila M, Tellez-Rojo MM, Mercado A, Hu H. The relationship between lead in plasma and whole blood in women. Environ Health Perspect2002;110:263-268.","DOI":"10.1289\/ehp.02110263"},{"key":"2020022801102182500_R59","doi-asserted-by":"crossref","unstructured":"Bergdahl IA, Gerhardsson L, Schutz A, Desnick RJ, Wetmur JG, Skerfving S. Delta-aminolevulinic acid dehydratase polymorphism: influence on lead levels and kidney function in humans. Arch Environ Health1997;52:91-96.","DOI":"10.1080\/00039899709602870"},{"key":"2020022801102182500_R60","doi-asserted-by":"crossref","unstructured":"Bergdahl IA, Grubb A, Schutz A, Desnick RJ, Wetmur JG, Sassa S, et al. Lead binding to delta-aminolevulinic acid dehydratase (ALAD) in human erythrocytes. Pharmacol Toxicol1997;81:153-158.","DOI":"10.1111\/j.1600-0773.1997.tb02061.x"},{"key":"2020022801102182500_R61","unstructured":". US Environmental Protection Agency. Air quality criteria for lead. EPA 600\/8-83-028F1986 US Environmental Protection Agency, Office of Research and Development, Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office Research Triangle Park, NC. ."},{"key":"2020022801102182500_R62","doi-asserted-by":"crossref","unstructured":"Raghavan SR, Culver BD, Gonick HC. Erythrocyte lead-binding protein after occupational exposure. I. Relationship to lead toxicity. Environ Res1980;22:264-270.","DOI":"10.1016\/0013-9351(80)90138-3"},{"key":"2020022801102182500_R63","doi-asserted-by":"crossref","unstructured":"Teisinger J, Srbova J. The value of mobilization of lead by ethylenediamine-tetra-acetate in the diagnosis of lead poisoning. Br J Ind Med1959;16:148-152.","DOI":"10.1136\/oem.16.2.148"},{"key":"2020022801102182500_R64","doi-asserted-by":"crossref","unstructured":"Emmerson BT. Chronic lead nephropathy: the diagnostic use of calcium EDTA and the association with gout. Australas Ann Med1963;12:310-324.","DOI":"10.1111\/imj.1963.12.4.310"},{"key":"2020022801102182500_R65","unstructured":"Vitale LF, Joselow MM, Wedeen RP, Pawlow M. Blood lead\u2014an inadequate measure of occupational exposure. J Occup Med1975;17:155-156."},{"key":"2020022801102182500_R66","doi-asserted-by":"crossref","unstructured":"Wedeen RP. Use of the CaNa2 EDTA Pb-mobilization test to detect occult lead nephropathy. Uremia Invest1985\u201386;9:127-130.","DOI":"10.3109\/08860228509088200"},{"key":"2020022801102182500_R67","doi-asserted-by":"crossref","unstructured":". BrangstrupHansen J, Dossing M, Paulev PE. Chelatable lead body burden by calcium-disodium EDTA and blood lead concentration in man. J Occup Med1981;23:39-43.","DOI":"10.1097\/00043764-198101000-00017"},{"key":"2020022801102182500_R68","doi-asserted-by":"crossref","unstructured":"Havelda CJ, Sohi GS, Richardson CE. Evaluation of lead, zinc, and copper excretion in chronic moonshine drinkers. South Med J1980;73:710-715.","DOI":"10.1097\/00007611-198006000-00008"},{"key":"2020022801102182500_R69","doi-asserted-by":"crossref","unstructured":"Jones MM, Basinger MM, Gale GR, Atkins LM, Smith AB, Stone A. Effect of chelated treatments on kidney, bone and brain lead levels of lead-intoxicated mice. Toxicology1994;189:91-100.","DOI":"10.1016\/0300-483X(94)90217-8"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/52\/1\/88\/32685161\/clinchem0088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/52\/1\/88\/32685161\/clinchem0088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T06:08:22Z","timestamp":1683266902000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/52\/1\/88\/5626607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2006,1,1]]},"published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2005.051128","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2006,1,1]]},"published":{"date-parts":[[2006,1,1]]}}}